Table 2. Preclinical study of animals bearing TS/A tumours.

	Group I [111In]-DOTA-dLVT and cold OT	Group II [111In]-DOTA-dLVT only
Tumour (%ID g−1)	0.079	0.230
Blood (%ID g−1)	0.017	0.030
Kidney (%ID g−1)	1.693	3.559
Liver (%ID g−1)	0.075	0.162
Tumour/blood ratio	4.54	7.58
Tumour/kidney ratio	0.05	0.06
Tumour/liver ratio	1.05	1.42

Balb/c mice bearing TS tumours positive for the human OTR were intravenously injected with [¹¹¹In]-DOTA-dLVT. Five mice were injected with 50 μg of cold OT 30 min before receiving the radiotracer (Group I); five mice received only the radiotracer (Group II). A 20-fold dilution of the injected dose (average activity 74 kBq) was used as a standard for the total administered activity. Activity is expressed as a percentage of injected dose (%ID) g⁻¹ of tissue, and ratios of uptake between tumour, blood, kidney and liver were calculated. The data are averages of five replicates; the activity remaining in the tail was also considered and subtracted from the total activity for the calculations.